IGF-1 Tracks Recovery in Anorexia Nervosa and Predicts Hormonal Restoration
IGF-1 levels remain suppressed in anorexia nervosa and only partially normalize with weight restoration, signaling metabolic and reproductive recovery.
Summary
A new study using UK Biobank data and a clinical cohort of women with anorexia nervosa (AN) found that IGF-1 levels follow a graded pattern: lowest in active AN, intermediate after weight restoration, and highest in healthy controls. Over 12 months of treatment, IGF-1 rose significantly, and higher baseline BMI predicted greater increases. Crucially, IGF-1 levels independently predicted the return of menstrual function, suggesting it reflects more than just body weight. The hormone correlated with insulin, glucose, and thyroid hormone (FT3), and inversely with growth hormone, confirming GH resistance as a feature of AN. Clinicians may find IGF-1 a useful biomarker for tracking true metabolic recovery beyond BMI normalization alone.
Detailed Summary
Anorexia nervosa (AN) is among the most medically serious psychiatric conditions, causing widespread endocrine disruption that extends well beyond visible weight loss. One underexplored casualty is insulin-like growth factor 1 (IGF-1), a key mediator of growth hormone signaling. This study aimed to characterize how IGF-1 behaves across different stages of AN and whether it tracks meaningful aspects of recovery.
Researchers combined two complementary datasets: a cross-sectional analysis from the UK Biobank including 129 women with current AN, 2,380 weight-restored AN individuals, and 2,380 matched healthy controls; and a longitudinal clinical cohort of 189 women with AN assessed at baseline and again at 12 months of specialist treatment.
The cross-sectional data revealed a clear hierarchy: IGF-1 was lowest in active AN, intermediate in weight-restored individuals, and highest in healthy controls. This graded pattern suggests that even after weight normalization, IGF-1 dysregulation persists. In the clinical cohort, IGF-1 correlated positively with insulin, glucose, and free T3, and negatively with growth hormone — a signature consistent with growth hormone resistance, where GH rises but fails to stimulate IGF-1 production. Over 12 months of treatment, IGF-1 increased significantly (p = 0.003), with higher baseline BMI predicting larger gains. Independently of BMI, higher IGF-1 was strongly associated with the return of menstrual function (p < 0.001).
These findings position IGF-1 as a sensitive biomarker of metabolic state and reproductive recovery in AN — potentially more informative than weight alone. For clinicians, this raises the possibility of using serial IGF-1 measurements to gauge depth of recovery and physiological normalization.
Caveats include the abstract-only basis for this summary, the exclusively female sample, and uncertainty about whether IGF-1 fully normalizes over longer follow-up periods beyond 12 months.
Key Findings
- IGF-1 follows a graded pattern: lowest in active AN, partial recovery after weight restoration, highest in healthy controls.
- IGF-1 increased significantly over 12 months of treatment; higher baseline BMI predicted greater IGF-1 gains.
- Higher IGF-1 independently predicted return of menstrual function, regardless of BMI (p < 0.001).
- IGF-1 inversely correlated with GH levels, confirming growth hormone resistance as a core feature of AN.
- IGF-1 may serve as a biomarker of true metabolic recovery beyond weight normalization alone.
Methodology
The study combined a cross-sectional UK Biobank analysis (129 current AN, 2,380 weight-restored AN, 2,380 age/sex/BMI-matched controls) with a longitudinal clinical cohort (189 women, baseline and 12-month follow-up). Cross-sectional design limits causal inference; the longitudinal arm adds temporal context but lacks a control comparator group.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The study included only adult women, limiting generalizability to men, adolescents, or other eating disorder presentations. It remains unclear whether IGF-1 fully normalizes beyond the 12-month observation window.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.